Synthetic Biologics is headquartered in Rockville, Maryland.
#Syn stocktwits trial#
Louis to conduct a Phase 1b/2a clinical trial of SYN-004. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center and a clinical trial agreement with Washington University School of Medicine in St. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics SYN-005 for the prevention and treatment of pertussis and VCN-11 to treat cancer. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. SYN-004 (ribaxamase) Designed to be co-administered with IV beta-lactam antibiotics, ribaxamase is an oral enzyme tablet that allows the IV antibiotic to treat infection while protecting the gut microbiome from dysbiosis and thus preventing Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host. Synthetic Biologics, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.